Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02364999 · ClinicalTrials.gov registry record · Phase 3
A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 719
- Enrollment target
NCT02364999 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 719 participants.
The verdict
NCT02364999, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 719 participants
- Enrollment target
Study Summary
This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous NSCLC.
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Bevacizumab-Pfizer
- DRUG Bevacizumab-EU
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 719 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02364999
The ClinicalTrials.gov registry entry for NCT02364999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 719 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT02364999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02364999 about?
NCT02364999 is a clinical study titled "A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC". This is a multinational, double-blind, randomized, parallel-group Phase 3 clinical trial evaluating the efficacy and safety of bevacizumab-Pfizer plus paclitaxel and carboplatin versus bevacizumab-EU plus paclitaxel and carboplatin in first-line treatment for patients with advanced (unresectable, lo...
What is the current status of trial NCT02364999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 719 participants. The study started on 2015-04. Estimated completion is 2017-12.
What interventions are being tested in trial NCT02364999?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Bevacizumab-Pfizer (DRUG), Bevacizumab-EU (DRUG).
Who is sponsoring clinical trial NCT02364999?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.